Minovia Therapeutics Announces Interim Data from Phase 2 Trial in Pearson Syndrome Demonstrating No Treatment-Related Serious Adverse Events and Preliminary Signal for Efficacy Measured by Growth

HAIFA, Israel, July 24, 2025 (GLOBE NEWSWIRE) -- Minovia Therapeutics Ltd. (“Minovia” or the “Company”), a clinical-stage biotechnology company developing novel therapies to treat mitochondrial diseases and combat age-related decline, announces positive interim results of the ongoing Phase 2 trial of the Company’s lead investigational compound MNV-201 in Pearson Syndrome, a fatal pediatric mitochondrial disease characterized by sideroblastic anemia (a disorder causing abnormal red blood cell development), failure to thrive and exocrine pancreas dysfunction. The interim analysis was presented at the United Mitochondrial Disease Foundation (UMDF) Annual Meeting on June 20, 2025. The analysis showed that MNV-201 has a positive safety profile even in this fragile patient population, currently meeting the Phase 2 trial’s primary safety endpoint.

Read more at globenewswire.com